Salarius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Decoy Therapeutics

10/03/2022 23:26

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of 9 cents​​ per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for a loss of 8 cents per share.
    * Reported revenue was zero​;  analysts expected $433.33
thousand. 
    * Salarius Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 9 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Salarius Pharmaceuticals Inc shares had fallen by 24.4%
this
quarter.
    * The company reported a quarterly loss of $4.1 million.
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $5.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated March 10 at 11:26 p.m.  ​All
figures in US dollars unless otherwise stated